Background: Type A insulin resistance (IR) is a rare form of severe congenital IR that is frequently caused by heterozygous mutations in the insulin recep-
Introduction
Type A insulin resistance (IR) is a rare form of severe insulin resistance (SIR) that is frequently caused by insulin receptor (INSR) dysfunction, which is due to heterozygous mutations in the INSR gene. 1 This condition usually presents after puberty and is characterized by IR, acanthosis nigricans, and hyperandrogenism in the absence of obesity or lipodystrophy; this phenotype is also called insulin-resistant diabetes mellitus with acanthosis nigricans (IRAN Type A). 2, 3 Defects in the INSR gene cause a wide spectrum of congenital diseases associated with IR. Disease severity can vary considerably and is generally correlated with INSR activity. In contrast with Type A IR, biallelic mutations of INSR result in the more severe Donohue syndrome (DS) or Rabson-Mendenhall syndrome (RMS). 2, 3 Although IRAN Type A requires appropriate intervention from the early stages of diabetes, proper diagnosis of the disease is challenging. It is presumed that many patients are overlooked, and that the reported prevalence of Type A IR (1/100 000) is less than the predicted prevalence (1/1000), which was calculated based on the most severe form with biallelic INSR mutations (1/4 000 000). [1] [2] [3] Furthermore, Type A IR is diagnosed more often in females than in males because females have more health problems associated with this condition (especially hyperandrogenism). Several background factors could account for the epidemiological discrepancies. First, patients with Type A IR develop diabetes after puberty and are not usually diagnosed during childhood. In addition, differential diagnosis of other forms of non-lipodystrophic SIR sometimes becomes a problem without genetic testing.
For definitive diagnosis, sequencing INSR is be the most reliable test, but diagnosis is not straightforward. Sequencing of INSR is time consuming and expensive, because INSR is large, with 21 exons. Moreover, some Type A IR patients have no mutations in the coding sequence of INSR but still have impaired expression, which is presumably caused by mutations in an unknown cis-regulatory element of INSR.
Insulin signaling has an important role in glucose metabolism and growth during the fetal period and in infancy. Impaired insulin signaling affects growth. However, the precise clinical course of Type A IR during childhood is not documented, even by auxological data. Elucidating the clinical details of Type A IR during childhood by including additional auxological data can help improve the early diagnosis of Type A IR.
Herein we report on six peripubertal patients with Type A IR, including four patients with an identified INSR mutation, and validate the clinical characteristics of Type A IR due to the INSR mutations compared with mutation-negative patients. To clarify the clinical features of Type A IR due to INSR mutation, we compared Type A IR patients with INSR mutations to those without mutations.
Methods

Case presentation
All patients were born to non-consanguineous Japanese parents and not previously diagnosed with diabetes mellitus (DM); profile summaries are given in Table 1 (33.6) . She was born prematurely with a low birth weight of 1926 g, but her gestational age was unknown because of a lack of prenatal checkups. Her developmental history was abnormal; she was brought up in a child welfare institute because she was neglected by her mother, who had mild mental retardation. The patient also had mild mental retardation (IQ 66), which was thought to be either familial or affected by the patient's perinatal history. The patient's familial history of DM was not known. Metformin treatment was started based on the diagnosis of Type A IR and the patient's HbA1c improved to 6.0% (42 mmol/mol) after 9 months.
Case 4
A 13-year-old female was referred to Soka Municipal Hospital because of glycosuria detected by a urine glucose-screening program. Laboratory data revealed 
DNA sequencing and deletion analysis of INSR
All exons including intron-exon junctions and cDNA of the INSR gene were analyzed by Sanger sequencing, as previously described. 4 The reference sequence was NG_008852.2 for genomic DNA and NM_000208.3 for cDNA.
Structural analysis of missense mutations on a threedimensional structure of the tyrosine kinase domain of INSR To evaluate the structural and/or functional effects of the missense mutations, the mutation residues were mapped onto the crystal structure of the tyrosine kinase (TK) domain of the INSR complex with a peptide substrate (Protein Data Bank [PDB] code: 1ir3). 5, 6 Known pathogenic mutations annotated in the UniProt (http:// www.uniprot.org/, accessed 12 June 2018) and ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/, accessed 12 June 2018) databases were also mapped onto the INSR structural model. Molecular graphics images were prepared using PyMOL (https://pymol.org/, accessed 12 June 2018).
Comparative study of birth weight between patients with SIR
To assess correlations between phenotype severity and birth weight, perinatal information was collected for patients with genetically proven SIR from previous reports. 3, 4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Birth weight SDSs were calculated based on a Japanese reference 21 and international standard.
22
For comparisons between groups, the significance of differences was evaluated using a Mann-Whitney U-test and one-way analysis of variance (ANOVA) followed by a Tukey-Kramer post test. In the present study, twosided P < 0.05 was considered significant. All statistical analyses were performed using SPSS Statistics ver.22.0 (IBM Corp., Armonk, NY, USA).
Results
The clinical and laboratory data of the six patients with clinically diagnosed Type A IR are summarized in Table 1 . All patients with INSR mutations (Cases 1-4) exhibited SIR, with HOMA-IR scores >10 and diabetic patterns based on oral glucose tolerance tests (OGTTs; blood glucose after OGTT >11 mmol/L). However, endocrinological profiles, including the severity of insulin resistance (insulin concentrations and HOMA-R), endogenous insulin concentrations (C-peptide concentrations and the insulin: C-peptide ratio), and the gonadotrophin-gonadal axis for androgen production, could not conclusively distinguish between mutation-positive and -negative patients. Consistent with previous reports, 2,23 patients with INSR mutations in the present study did not exhibit dyslipidemia. Cases 5 and 6, which lacked INSR mutations, developed fatty liver, which indicates a pathogenic mechanism other than INSR dysfunction, such as a lipid metabolism defect. All patients with INSR mutations received metformin, which normalized HbA1c within 1 year, indicating partial improvement of glycometabolism during adolescence, as reported previously. 24 Sequencing of INSR from the six patients revealed four heterozygous missense mutations, namely c.3436G > A (p.Gly1146Arg), c.3472C > T (p.Arg1158Trp), c.3601C > T (p.Arg1201Trp), and c.3602G > C (p.Arg1201Pro) in Cases 1, 2, 3, and 4, respectively. Genotype analyses of the parents revealed inheritance of the Gly1146Arg mutation from the father in Case 1, inheritance of the Arg1158Trp mutation from the father in Case 2 ( Figure S1 ), and inheritance of the Arg1201Pro mutation from the mother in Case 4 ( Fig. 1) (Fig. 2) and are conserved among vertebrates, which indicates that they are critically important for INSR function.
For the structural analysis, the four missense mutations were mapped onto the three-dimensional (3D) structure of the TK domain of INSR (Fig. 3a) , as determined by X-ray crystallography. 25, 26 The 3D model analysis revealed the critical importance of Gly (Fig. 3b-d) . In Arg 1201 , the amino acid substitutions of Arg to Trp or Pro on the residue would destroy the hydrogen bond network and alter the local conformation of the substrate-binding region, leading to impaired substrate binding. The structural analysis of the four mutations located in the TK domain suggested that all the mutations would impair INSR signaling through different molecular mechanisms at atomic resolution.
In Cases 5 and 6, direct sequencing of all exons and cDNA of INSR did not detect mutations, and antiinsulin antibodies were not detected in either case. These data indicate that pathogenic mechanisms other than INSR defects may have caused SIR in both cases.
To evaluate the effect of insulin signaling defects during the fetal period, we compared the SDSs of birth weight between patients with Donohue syndrome (DS), Rabson-Mendenhall syndrome (RMS), and Type A IR. In addition to the present cases, we collected perinatal information for 12 Japanese patients (five with Type A IR and seven with DS or RMS) and 28 patients from other countries (two with Type A IR, 15 with DS, and 11 with RMS) based on previous studies. 3, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 27 All birth weight SDSs for all nine patients with Type A IR were < 0 (mean [AESD] -1.65 AE 0.85; range from −0.72 to −3.28). Among Japanese patients, the birth weight SDSs of patients with Type A IR were significantly lower than those of the other group with SIR (−1.72 AE 0.91 vs −3.54 AE 0.72; P = 0.0118; Fig. 4a) . Similarly, the group comparative study that included data from other countries showed that birth weight SDSs were correlated with the severity of insulin signaling defects (Fig. 4b) . Conversely, there was no obvious correlation between genotype and birth weight SDS (Fig. 4b) .
Figure 1
Clinical features and family pedigrees of Case 4; III-1 is the proband. The proband and her mother (II-5) have a heterozygous insulin receptor (INSR) mutation, namely c.3602G > C (p.Arg1201-Pro). The proband's father (II-2) has no mutation. Severe insulin resistance was detected in the mother, but not in the father or brother (III-2). The proband's maternal grandmother (I-4) developed diabetes mellitus and required insulin therapy at the age of 41 years, and died at the age of 53 years.
Discussion
One aim of the present study was to identify a correlation between phenotype and genotype. First, we hypothesized that the clinical spectra could differ between Type A IR and other types of diabetes with IR, because other types of IR diabetes are assumed to be due to mutations of genes that are located downstream of intracellular insulin signals. Those molecules could mediate other intracellular signals, such as lipid metabolism, and would result in some additional clinical features other than IR (i.e. AN and PCOS in females, as well as hyperinsulinemia without severe obesity). Nonetheless, as reported previously, 23 there were no obvious differences in clinical phenotype, except for the absence of abnormal lipid metabolism (i.e. fatty liver, dyslipidemia, and high plasma adiponectin levels), between Type A IR due to INSR mutations and IR due to other factors. Alternatively, the extent of growth retardation during the fetal period was correlated with the severity of insulin signaling impairment. One major factor responsible for fetal growth is insulin, 28 and IR would affect growth more severely during the fetal than postnatal period. Indeed, in Type A IR, short stature is not a common clinical feature, but the mean SDS of the birth weight was less than −1. Those findings demonstrate that fetal growth very much depends on insulin signals, and approximately 50% of residual IR activity was not sufficient for full fetal growth. Further, our analysis revealed that the SDS of birth weight was significantly lower in individuals who were homozygous or compound heterozygous for INSR mutations (DS or RMS) than those who had heterozygous mutations (Type A IR). Consequently, the severity of insulin signaling impairment could be estimated.
All INSR mutations in the patients in the present study were located in the TK domain of the β-subunit, which contains 278 residues (from residue 1023 to residue 1290), which confirms previous reports that INSR mutations in the TK domain impair INSR activity more critically than those located in other domains. 7, 11, 29, 30 Indeed, most IR missense or nonsense mutations located outside the TK domain are thought to incompletely impair IR activity, 13, 27, 29, [31] [32] [33] and most asymptomatic carriers who were discovered by familial studies of RMS and DS have INSR mutations outside the TK domain. 4, [10] [11] [12] [13] [14] 18, [34] [35] [36] [37] The regional dependency of the residual activity would affect the penetrance of Type A IR due to heterozygous INSR mutation. This is one explanation for the epidemiological discrepancy in INSR deficiencies (i.e. the actual prevalence of Type A IR is markedly lower than the estimated prevalence based on the prevalence of the homozygous or compound heterozygous mutated type, RMS or DS).
The present study has several limitations. First, there was only a limited number of INSR mutation-deficient cases in this study. We speculate that elucidating the clinical features of growth and metabolism could assist in the early diagnosis of INSR deficiency, and further accumulation of genetically proven cases with detailed longitudinal observations would be of great benefit to diagnosing and treating INSR deficiency. Second, the etiologies of the two patients without INSR mutations were not identified. Recent studies reported that lipodystrophy-related genes are associated with SIR without apparent lipodystrophy, 38, 39 which indicates that numerous genes are candidates for SIR. To identify SIR-causative genes other than INSR, comprehensive genetic analyses, including next-generation sequencing, are necessary.
In conclusion, the present study reported a genotype-phenotype correlation of INSR and clinical features of four patients with genetically proven Type A IR. We suggest that the absence of dyslipidemia would be a clinical feature of IR with INSR mutation, although, with regard to endocrinological findings, no particular phenotypes associated with INSR mutations were identified. We suggest that the birth weight SDS could predict the residual activity of insulin signaling, and have reported a novel missense mutation: c.3602G > C (Arg1201Pro). Despite acceptable control during childhood and adolescence, long-term metabolic control has been reported to remain poor and diabetes complications are frequent in Type A IR patients. 40, 41 Thus, in addition to metformin, several future-proof treatments, including recently reported possible candidates (i.e. metreleptin, sodium-glucose cotransporter 2 inhibitor, and incretin therapies) 42, 43 should be introduced during childhood. To develop a treatment strategy for Type A IR, further accumulation of genetically proven cases with detailed clinical histories is essential. The birth weight SDS of nonJapanese patients was calculated based on international standards. 22 In Type A IR, six of seven subjects had heterozygous missense mutations. One subject had a heterozygous nonsense mutation. In Rabson-Mendenhall syndrome, nine subjects had missense mutations on both alleles, and three subjects had missense mutations on one allele and nonsense or frameshift mutations on the other allele. One subject had frameshift mutations on both alleles. In Donohue syndrome, seven subjects had missense mutations on both alleles. Five subjects had missense mutations on one allele, and frameshift mutations on the other allele. Eight subjects had nonsense or missense mutations on both alleles. The boxes show the interquartile range, with the median value indicated by the horizontal line; whiskers show the range.
